Patricia Weiser, Pharm.D.

In a cohort study of 496 lung cancer survivors, 11.5% had a recurrence during a five-year follow-up period, and 5.6% had cancer outside the lungs.

Researchers found that less than half (43.8%) of the patients underwent surveillance imaging consistent with recommended guidelines.

A national survey of 157 patients with non-small cell lung cancer found that all groups prioritized extending life, but treatment preferences, including concerns about side effects and quality-of-life tradeoffs, differed across racial and ethnic groups.

Tumor infiltrating lymphocyte (TIL) therapy uses immune cells harvested directly from a patient’s tumor.

A study of more than 4,600 Medicare patients links treatment with Keytruda (pembrolizumab) to improved survival outcomes in adults 66 and older treated for metastatic non-small cell lung cancer.

The national five-year survival rate for lung cancer has climbed to nearly 30%, up from 18% from eight years ago, according to the American Lung Association.

Study participants who used the mPATH-Lung program were 60% more likely to undergo lung cancer screening, than particpants who did not use the program.

Although neuroendocrine tumors of the digestive system have been studied, far less is known about those that develop in the lungs, even as their incidence appears to be on the rise.

Most of the exposure to misinformation about cancer treatment occurs in conversations with family and friends and on social media.

The FDA approved sunvozertinib, sold as Zegfrovy, in July 2025.

Patients with advanced non-small cell lung cancer were negatively affected by exposure to antibiotics, PPIs, and high-dose steroids at the start of treatment with Keytruda (pembrolizumab), French researchers found.

Disparities emerged in receipt of systemic therapy, particularly in lung cancer.

The study finds less than 1 in 4 go on to second-line treatment.

National registry study finds overall survival improved across the board after the introduction of immune checkpoint inhibitor (ICI) drugs, but gaps remained. Uninsured patients realized smaller gains compared with those with private insurance.

Patients using steroids, especially at high-doses, before taking immune checkpoint inhibitors for non–small cell lung cancer were more likely to have brain metastases.

The investigational agent, zipalertinib, received the breakthrough designation from the FDA in January 2022

Datroway (datopotamab deruxtecan) is the first TROP2-directed therapy approved for advanced lung cancer in the U.S.

The study is the first, to the researchers’ knowledge, to evaluate both survival and cost metrics across non-small cell lung cancer biomarker subtypes.

Findings mark the first time a neoadjuvant immunotherapy regimen has demonstrated a significant survival benefit in a randomized phase 3 trial of a solid tumor.

Tracking the trajectory of symptoms may be an improvement over the traditional way of collecting patient-reported outcomes

Ryoncil is the first mesenchymal stromal cell therapy to be approved in the United States.

Immune checkpoint inhibitors, such as Opdivo (nivolumab) and Keytruda (pembrolizumab), have been a huge advance in the treatment of non-small cell lung cancer. But it is open question whether they should be combined with traditional chemotherapy.

Researchers are exploring the topic of "time toxicity" — how much time patients spend receiving care. This study is the first to directly compare time spent in care between clinical trial participants and routine care patients receiving the same treatments.

John Levine, M.D., a graft-versus-host-disease expert at the Icahn School of Medicine at Mount Sinai in New York, makes a case for biomarkers in a review article published in the American Journal of Hematology.

New research shows that Medicaid expansion was linked to a 2.1% increase in timely lung cancer surgeries and a 2.8% rise in procedures at high-volume hospitals, highlighting how policy changes can impact cancer care access.